Premium
Single nucleotide polymorphisms in fibroblast growth factor 23 gene, FGF 23 , are associated with prostate cancer risk
Author(s) -
Kim Hae Jong,
Kim KyeoungHwa,
Lee Jaehyouk,
Oh Jong Jin,
Cheong Hyun Sub,
Wong Ee Lin,
Yang BeomSeok,
Byun Seok Soo,
Myung Soon Chul
Publication year - 2014
Publication title -
bju international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 1464-4096
DOI - 10.1111/bju.12396
Subject(s) - single nucleotide polymorphism , prostate cancer , odds ratio , case control study , haplotype , prostate , oncology , cancer , risk factor , medicine , locus (genetics) , biology , population , genetics , genotype , gene , environmental health
Objective To determine whether sequence variants within the FGF 23 gene are associated with the risk of developing prostate cancer in a K orean population.Patients and Methods Five common single nucleotide polymorphisms ( SNPs ) in the FGF 23 gene were assessed in 272 patients with prostate cancer and 173 control subjects with benign prostatic hyperplasia. Single‐locus analyses were conducted using conditional logistic regression. In addition, we performed a haplotype analysis for the five FGF 23 SNPs tested.Results Three SNPs in the FGF 23 gene (rs11063118, rs13312789 and rs7955866) were associated with an increased risk of prostate cancer in our study population. Odds ratios for homozygous variants vs wild‐type variants ranged from 1.68 (95% confidence interval [ CI ]: 1.15–2.46) to 1.79 (95% CI : 1.16–2.75).Conclusion This is the first study showing that genetic variations in FGF 23 increase prostate cancer susceptibility.